(Press-News.org) BOSTON––Thousands of patients with an advanced form of lung cancer that carries a specific dysfunctional gene are likely to fare better if treated with a targeted therapy than with traditional chemotherapy, report Dana-Farber Cancer Institute researchers and a team of international collaborators.
In a trial involving patients with non-small cell lung cancer (NSCLC) whose tumor cells harbored an abnormal ALK gene, those who received the oral drug crizotinib, which acts directly on ALK, went a median time of 7.7 months before their disease began to worsen, compared to 3 months for patients who received traditional chemotherapy. Patients treated with crizotinib also had a better quality of life than those treated with standard chemotherapy. The findings will be released as an advanced online publication by the New England Journal of Medicine on June 1.
"This study demonstrates the value of testing lung cancer tissue for an ALK rearrangement, and it underscores the potential of cancer genomics to target cancer treatments to each patient," says the study's senior author, Pasi A. Jänne, MD, PhD, who is the director of the Lowe Center for Thoracic Oncology of Dana-Farber. "ALK now becomes the second abnormal gene that we are able to successfully target in lung cancer with drugs other than chemotherapy." Lung cancers with the first such gene, EGFR, are now commonly treated with EGFR inhibitors before chemotherapy.
The lead author of the study is Alice Shaw, MD, PhD, of Massachusetts General Hospital.
NSCLC is the most common form of lung cancer, striking nearly 200,000 people in the U.S. each year. Although abnormal ALK is found in only about 5 percent of NSCLC cases, that translates into more than 5,000 new patients annually who could potentially benefit from crizotinib therapy, the study authors state.
The phase 3 trial described in the paper involved 347 patients with advanced or metastatic NSCLC who had already been treated with standard chemotherapy. The most common side effects associated with crizotinib therapy – visual disorders, gastrointestinal problems, elevated liver enzymes, and leg swelling – were generally mild, Jänne said, and are markedly different than the fatigue and hair loss associated with chemotherapy.
The abnormality in ALK that arises in NSCLC is not, strictly speaking, a mutation (a change in the sequence of DNA within a gene). Rather, it results from a chromosomal rearrangement, in which the structure of a chromosome – the scaffolding of genetic material – is altered.
Crizotinib is a drug agent that takes aim at key enzymes within cells called kinases, which are often abnormal in cancer. Originally designed to block a kinase called MET, it was later discovered to target ALK as well. At the time, it wasn't known that ALK was sometimes abnormal in lung cancer. The discovery that it is abnormal in a small percentage of NSCLCs led to its testing against the disease.
INFORMATION:
Financial support for the study was provided by Pfizer, Inc.
— Written by Rob Levy
About Dana-Farber Cancer Institute
Dana-Farber Cancer Institute is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber/Harvard Cancer Center, designated a comprehensive cancer center by the National Cancer Institute. It provides adult cancer care with Brigham and Women's Hospital as Dana-Farber/Brigham and Women's Cancer Center and it provides pediatric care with Boston Children's Hospital as Dana-Farber/Boston Children's Cancer and Blood Disorders Center. Dana-Farber is the top ranked cancer center in New England, according to U.S. News & World Report, and one of the largest recipients among independent hospitals of National Cancer Institute and National Institutes of Health grant funding. Follow Dana-Farber on Facebook and on Twitter: @danafarber.
Targeted therapy boosts lung cancer outcomes
2013-06-01
ELSE PRESS RELEASES FROM THIS DATE:
New drug improves progression-free survival, shrinks tumors in rare cancer for first time
2013-06-01
CHICAGO, JUNE 1, 2013 — The experimental drug selumetinib is the first targeted therapy to demonstrate significant clinical benefit for patients with metastatic uveal melanoma, according to new Memorial Sloan-Kettering Cancer Center research presented on Saturday, June 1, at the 49th annual meeting of the American Society of Clinical Oncology (ASCO).
The findings are potentially practice-changing for a historically "untreatable disease." Though uveal melanoma is rare — there are only 2,500 cases diagnosed in the United States each year — about half of patients will develop ...
No increased risk of infection for long-term sex partners of people with HPV-related oral cancers
2013-06-01
Spouses and long-term partners of patients with mouth and throat cancers related to infection with the human papilloma virus (HPV) appear to have no increased prevalence of oral HPV infections, according to results of a multicenter, pilot study led by Johns Hopkins investigators. The study's results suggest that long-term couples need not change their sexual practices, say the scientists.
"While we can't guarantee that the partners of patients will not develop oral HPV infections or cancers, we can reassure them that our study found they had no increased prevalence of ...
Acidifying oceans could spell trouble for squid
2013-06-01
Acidifying oceans could dramatically impact the world's squid species, according to a new study led by Woods Hole Oceanographic Institution (WHOI) researchers and soon to be published in the journal PLOS ONE. Because squid are both ecologically and commercially important, that impact may have far-reaching effects on the ocean environment and coastal economies, the researchers report.
"Squid are at the center of the ocean ecosystem—nearly all animals are eating or eaten by squid," says WHOI biologist T. Aran Mooney, a co-author of the study. "So if anything happens to ...
Procedures saving limbs of more peripheral arterial disease patients, Mayo Clinic finds
2013-06-01
SAN FRANCISCO -- Peripheral arterial disease is a common circulation problem in which reduced blood flow can lead to complications that jeopardize the limbs, possibly even requiring amputation. Procedures known as revascularization have reduced the need for amputations 40 percent over two decades, Mayo Clinic research shows. The findings were among several studies presented at the Society for Vascular Surgery annual meeting in San Francisco.
In the amputation study, Mayo researchers analyzed patients in the Rochester Epidemiology Project, a National Institutes of ...
Exposure to general anaesthesia could increase the risk of dementia in elderly by 35 percent
2013-06-01
Exposure to general anaesthesia increases the risk of dementia in the elderly by 35%, says new research presented at Euroanaesthesia, the annual congress of the European Society of Anaesthesiology (ESA). The research is by Dr Francois Sztark, INSERM and University of Bordeaux, France, and colleagues.
Postoperative cognitive dysfunction, or POCD, could be associated with dementia several years later. POCD is a common complication in elderly patients after major surgery. It has been proposed that there is an association between POCD and the development of dementia due ...
Catastrophic climatic events leave corals facing a decade-long fight for recovery
2013-06-01
Marine conservationists from Plymouth University, and the Universidad Federal da Bahia in Brazil, have spent more than 17 years analysing the diversity and density of coral colonies off the coast of South America.
That coincided with the catastrophic El Niño event of 1997-98, creating an opportunity for the first detailed assessment of the long-term impact a major environmental incident of this nature can have on coral assemblages.
Professor Martin Attrill, Director of Plymouth University's Marine Institute, said: "Coral reefs are perhaps the most diverse marine ecosystem ...
Oncogene mutation hijacks splicing process to promote growth and survival
2013-06-01
An international team of researchers – led by principal investigator Paul S. Mischel, MD, a member of the Ludwig Institute for Cancer Research and professor in the Department of Pathology at the University of California, San Diego School of Medicine – has found that a singular gene mutation helps brain cancer cells to not just survive, but grow tumors rapidly by altering the splicing of genes that control cellular metabolism.
The findings are published online in the journal Cell Metabolism.
Mischel, who heads the Ludwig Institute's molecular pathology laboratory based ...
Investigators link poultry contamination on farm and at processing plant
2013-06-01
Researchers at the University of Georgia, Athens, have identified a strong link between the prevalence and load of certain food-borne pathogens on poultry farms, and later downstream at the processing plant. They report their findings in a manuscript published ahead of print in the journal Applied and Environmental Microbiology.
"This study suggests that reducing foodborne pathogen loads on broiler chicken farms would help to reduce pathogen loads at processing, and may ultimately help to reduce the risk of foodborne illness," says Roy Berghaus, an author on the study. ...
Microbial changes regulate function of entire ecosystems
2013-06-01
A major question in ecology has centered on the role of microbes in regulating ecosystem function. Now, in research published ahead of print in the journal Applied and Environmental Microbiology, Brajesh Singh of the University of Western Sydney, Australia, and collaborators show how changes in the populations of methanotrophic bacteria can have consequences for methane mitigation at ecosystem levels.
"Ecological theories developed for macro-ecology can explain the microbial regulation of the methane cycle," says Singh.
In the study, as grasslands, bogs, and moors ...
Surges in latent infections: Mathematical analysis of viral blips
2013-06-01
Philadelphia, PA—Recurrent infection is a common feature of persistent viral diseases. It includes episodes of high viral production interspersed by periods of relative quiescence. These quiescent or silent stages are hard to study with experimental models. Mathematical analysis can help fill in the gaps.
In a paper titled Conditions for Transient Viremia in Deterministic in-Host Models: Viral Blips Need No Exogenous Trigger, published last month in the SIAM Journal on Applied Mathematics, authors Wenjing Zhang, Lindi M. Wahl, and Pei Yu present a model to study persistent ...